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Abstract 
Presymptomatic Testing (PST) for Huntington’s disease (HD) is available since 1986 and its impact on carriers 
and non-carriers is not yet fully clear. It is important to understand its psychological impact so that the PST 
protocols are best suited to the subjects at-risk. Preventing a negative psychological impact is the ultimate 
purpose of the genetic counselling process. This study addresses the long-term negative psychological impact 
assessment of PST for HD. The sample consisted of 29 subjects that were 50% at-risk for HD, and had 
performed the PST for at least three years ago. Participants answered the sociodemographic questionnaire and 
the Brief Symptom Inventory, the Zung Self-Rating Anxiety Scale, and the Beck Depression Inventory. Although 
most of the sample does not present clinically significant psychopathology values, 6 subjects present a Positive 
Symptoms Distress Index value which is equal to or greater than 1.7; 7 subjects present a value which is equal to 
or greater than 40 of anxiety; and 7 subjects present mild depression. Symptomatic carriers, who underwent the 
PST less time ago, present worse psychopathological symptoms, depression and anxiety. Subjects with this 
profile should have a more intense and personalized psychological and social support, aiming to prevent the risk 
of suicide and to improve the quality of their lives. 
Keywords: Presymptomatic Testing (PST), Preditive genetic testing, Huntington´s Disease (HD), Long-term 
Psychological Impact, Late-onset disease 
 
1. Introduction 
Huntington´s Disease (HD) is a rare autosomal-dominant inherited progressive neurodegenerative disorder of the 
central nervous system, characterized by unwanted choreatic movements, behavioral and psychiatric 
disturbances, and dementia1. HD is caused by an expansion of a CAG repeat in the Huntingtin (HTT) gene, 
which leads to an expanded polyglutamine tract in the pervasive expressed HTT protein2. An excessive number 
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of CAG repeats in the gene results in a protein containing an excessive number of glutamine units and the 
expanded polyglutamine sequence in the Huntingtin protein is toxic to brain cells. The prevalence of this disease 
is 3-7: 100.000 whereas nearly 20: 100.000 are carriers of the gene responsible for the disease3.  
There is a prodrome of HD, that is, symptoms of the presence of a disease prior to the development of 
the full clinical syndrome, that may appear up to several years before the onset of motor symptoms4. There is 
also a triad of clinical impairments in HD patients: motor, cognitive and emotional features. The psychiatric 
manifestations cause significant morbidity and encompass the full spectrum of psychiatric illnesses5. HD is 
associated with affective disorders, irritability, apathy and psychosis5. However, high rates of psychiatric 
disturbances have also been observed in HD family members who do not carry the genetic mutation6. Some 
authors have also reported psychiatric and behavioral comorbidities in these subjects7,8, including the risk of 
suicidal behavior9-12. It is, however, difficult to prove that suicide may be a consequence resulting from the 
impact of the predictive test and not from the disease itself. In a study11, it was found that the number of deaths 
due to suicide among subjects with HD is almost four times greater than the corresponding proportion for the 
U.S. Caucasian population. However, there seems to be no consensus regarding the stages where this suicide risk 
is increased. In another study12, it was found that suicide may occur more frequently in the early stages of the 
illness, but other authors have identified two critical periods for increased risk of suicide in HD: immediately 
before receiving a diagnosis of HD and in the middle stage of the disease, when independence diminishes9.  
Suicide occurred more frequently in the early to middle stages of the illness11. Possibly due to that, suicide has 
not been identified as the most serious manifestation of the negative psychological impact of Presymptomatic 
Testing (PST) for HD.  
The first symptoms of HD usually begin at the age of 35–45 years, but there is a wide variation in its 
onset. There is no cure for HD, nor treatment that can delay or slow the progression of the disease and so HD can 
only be treated to alleviate the symptoms13.  
Genetic counseling provides information and support to people who have been, or may be, at-risk for 
genetic disorders. The practice of genetic counselling gives rise to many ethical dilemmas, and counsellors need 
to be aware of the principles of biomedical ethics, which are: respect for autonomy, beneficence, non-
maleficence and justice. PST guidelines for HD were published by an Ad Hoc Committee in 199414. In 2011, at 
the World Congress Meeting on HD, a proposal was made for the guidelines to be reviewed every two years in 
conjunction with the World Congress Meeting.  
The experience of genetic counselling is seen as an opportunity for discussing problems or is associated 
with feelings of disempowerment. Thus, PST may be a journey of empowerment, an ambivalent process or a 
poor experience15. Many people who seek genetic counseling decide not to know the results of the genetic 
testing. Analyzing why there are persons who reject the predictive testing and others no, it was studied the 
determinants for undergoing or not undergoing the PST: maturity of the individual at risk (related to age); ability 
to cope with a positive test result; experience of living with HD sufferers; information about testing and 
psychological support; attitude of the family; social visibility of genetic testing; personality and temperament of 
each subject at risk of HD16. Receiving a test result is one of the transition points in the life of an individual at-
risk for any genetic disease. In fact, the emotional impact of the test result is not always in accordance to the test 
result itself, because some mutation carriers may feel relieved after knowing their status15, 17. 
Several different authors studied the PST psychosocial impact in a middle and long-term period of time18-21. 
They all found mostly no evidence of negative psychological impact of the PST in the middle and long-term. 
However, a minority of subjects in this study presents values indicating negative psychological impact of the 
PST. That is why it is so important to determine which are the most affected subjects, aiming an adequate 
psychological intervention in order to avoid the risk of suicide. 
 
2. Materials and Methods 
2.1 Object of the study 
This quantitative study addresses the assessment of PST long-term psychological impact for HD, studying 
psychopathological, depression and anxiety symptoms.  
 
2.2 Participants 
The sample consisted of 29 subjects, aged over 20 years, that were 50% at-risk for HD, and had performed the 
PST for at least three years ago (Table 1). 
Table 1 presents the sociodemographic characteristics of the sample of this study, which is mostly 
female, married or in unmarried unions, with an average age of 44.52 years, composed by housekeepers, carriers 
and having performed the PST for about 5.72 years, on average. 
 
2.3 Measures 
The instruments used in this study were a sociodemographic questionnaire, the Brief Symptom Inventory 
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(BSI)22,23, the Zung Self-Rating Anxiety Scale (SAS)24,25; and the Beck Depression Inventory (BDI)26,27.  
The sociodemographic questionnaire included questions regarding gender, age, marital status, 
profession, PST result - non-carrier or carrier, current status - non-carrier, asymptomatic carrier or symptomatic 
carrier, and time after PST result. BSI aimed to assess psychopathological symptoms, SAS aimed to assess 
anxiety and BDI aimed to assess depression. 
 
2.4 Procedures 
The guidelines for this investigation were accepted by the Institute for Molecular and Cell Biology (IBMC) 
Ethics Committee. The guarantee of the confidentiality of the data was made clear. Additionally, the informed 
consent to voluntary collaborate in the research was obtained.  
In this study, all subjects had previously attended genetic counseling consultations in the Center for 
Preventive and Predictive Genetics (CGPP), IBMC, between January 2005 and July 2015, in order to know their 
genetic status for HD. The only inclusion criteria in this study was that the participants had completed the one 
year PST protocol in CGPP service, for at least three years, before participating in the study. 
Participants were contacted by mail, one time only, to answer the sociodemographic questionnaire and 
the BSI, SAS, and BDI instruments. A six-month time frame was respected to receive the participant´s responses 
by mail. 
Table 1 
Sociodemographic characterization of the sample (n = 29) 
Variables 
Total 
(n = 29) 
Gender 
Female 
Male 
 
16 (55.2%) 
13 (44.8%) 
Age 
Minimum 
Maximum 
M = 44.52; SD = 14.21 
21 
71 
Marital status 
Single 
Married or unmarried union 
Divorced or separated 
Widow or Widower  
 
9 (31.0%) 
16 (55.2%) 
2 (6.9%) 
2 (6.9%) 
Profession 
Pensioner 
Unemployed 
Student  
Employed 
 
9 (31.0%) 
2 (6.9%) 
2 (6.9%) 
16 (55.2%) 
PST result 
Non-carrier 
Carrier 
 
14 (48.3%) 
15 (51.7%) 
Current status 
Non-carrier 
Asymptomatic carrier 
Symptomatic carrier 
 
14 (48.3%) 
10 (34.5%) 
5 (17.2%) 
Time in years after PST result 
Less or equal to 5 
6 or more 
M = 5.72 [3-10]; SD = 2.02 
15 (51.7%) 
14 (48.3%) 
M = Mean; SD = Standard deviation  
  
2.5 Data Analysis 
Since the sample of this study follows a non-normal distribution, confirmed using the Kolmogorov-Smirnov test 
(K–S test or KS test) [0.379 (24) = 0.000], and since the sample size is small, non-parametric test for 
independent samples were used: the Mann-Whitney test for dichotomous variables, and the Kruskal-Wallis test 
for non-dichotomous variables. Correlations were calculated through the Spearman's rank correlation coefficient 
or Spearman's rho. 
Collected data were quantitatively analyzed using the SPSS IBM software, version 22.  
 
3. Results 
In Table 2, normative means of BSI scales and indices22 are presented to the general Portuguese population and 
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to the Portuguese population presenting emotional disturbances, as well as for the population in this study, i.e., 
subjects who took the PST for HD at least 3 years ago.  
Table 2 
Comparison of BSI scales and indices mean for the general Portuguese population, the Portuguese population 
with emotional disturbances and the population of the present study 
 
General Portuguese 
population 
Portuguese population 
with emotional 
disturbances 
Population of the present 
study 
Canavarro22 
BSI scales and 
indices 
M SD α M SD M SD α 
Somatization 0.573 0.916 0.80 1.355 1.004 0.571 0.711 0.88 
Obsessive-
compulsive 
1.290 0.878 0.77 1.924 0.925 1.012 0.855 0.88 
Interpersonal 
Sensitivity 
0.958 0.727 0.76 1.597 1.033 0.565 0.777 0.87 
Depression 0.893 0.722 0.73 1.828 1.051 0.667 0.762 0.86 
Anxiety 0.942 0.766 0.77 1.753 0.940 0.641 0.651 0.81 
Hostility 0.894 0.784 0.76 1.411 0.904 0.763 0.859 0.93 
Phobic Anxiety 0.418 0.663 0.62 1.020 0.929 0.222 0.494 0.80 
Paranoid Ideation 1.063 0.789 0.72 1.532 0.850 0.704 0.619 0.71 
Psychoticism 0.668 0.614 0.62 1.403 0.825 0.482 0.566 0.65 
GSI 0.835 0.480 - 1.430 0.705 0.638 0.595 - 
PSTI 26.993 11.724 - 37.349 12.166 19.172 13.385 - 
PSDI 1.561 0.385 - 2.111 0.595 1.502 0.540 - 
M = Mean; SD = Standard deviation; α = Cronbach's alpha; GSI = General Severity Index; PSTI = Positive 
Symptoms Total, PSDI = Positive Symptom Distress Index 
When comparing the normative values of the general population of the BSI Portuguese version22 with 
the values of the present study, it can be concluded that the present sample has lower values than those of the 
general population in all of the BSI scales and in all indices. Cronbach's alpha (α) values of the present sample 
are all higher than those found by the author of the Portuguese version (Table 2), except with regard to the 
paranoid ideation subscale. 
Of the 29 subjects of the sample, 23 (79.3%) present a Positive Symptom Distress Index (PSDI) value 
below the cutoff point proposed by the author (1.7)22 and 6 subjects (20.7%) a value equal to or greater than 1.7. 
Of these 6 subjects, 5 are carriers - 2 are asymptomatic and 3 are symptomatic. 
A comparison between the BSI scales and General Severity Index (GSI), Positive Symptoms Total 
(PSTI) and PSDI values in relation to the independent variables of this study was carried out. Only statistically 
significant results are presented. Students and employees present significantly lower values of the PSDI that 
pensioners and the unemployed (p = 0.046). Unemployed and employed present significantly lower levels of 
phobic anxiety than pensioners and students (p = 0.015). Regarding PST result, carriers present higher values 
than non-carriers, in what respects obsessive-compulsive (p = 0.018), depression (p = 0.020), and anxiety scales 
and PSDI. Regarding current status, symptomatic carriers present significantly higher values than asymptomatic 
carriers and then non-carriers, both regarding the obsessive-compulsive scale (p = 0.015) and PSDI (p = 0.004). 
Regarding the time after PST result (that refers to the number of years that the subjects performed the 
PST when this study was carried out and that was converted into a variable which splits the number of years in 
two groups - ≤ 5 years and ≥ 6 years), subjects which underwent the PST a smaller number of years ago (≤ 5) 
present higher levels of somatization (p = 0.017), anxiety (p = 0.044), GSI (p = 0.038), PSTI (p = 0.049), and 
PSDI (p = 0.049) than those who underwent the PST more years ago (≥ 6). 
In Table 3, normative means of BDI scales and total BDI26 are presented to the general Portuguese 
population, as well as for the population in this study, i.e., subjects who took the PST for HD at least 3 years ago. 
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Table 3 
Comparison of BDI scale sand Total BDI mean for the general Portuguese population and the population of the 
present study 
 
General Portuguese population  
Vaz Serra and Pio Abreu26  
Population of the present 
study 
BDI scales 
and total BDI 
Absence of 
depression 
Mild 
depression 
Moderate 
depression 
Severe 
depression 
α M SD α 
Cognitive-
affective 
depression 
- - - - - 0.331 0.422 0.86 
Somatic or 
performance 
depression 
- - - - - 0.341 0.437 0.72 
Total BDI 0 – 12 12 - 18 18 - 24 > 24 0.81 7.039 8.553 0.90 
ni (present 
study) 
22 (75.9%) 4 (13.8%) 1 (3.4%) 2 (6.9%) - - - - 
M = Mean; SD = Standard deviation; α = Cronbach's alpha; ni = absolute frequency  
When analyzing Table 3, alpha values are quite high, except with respect to the somatic or performance 
subscale. As shown in Table 3, the authors of BDI26 consider different levels of depression. The majority of the 
sample shows absence of depression, while 24.1% (7 subjects) of the sample present depression. 6 of these 7 
subjects are carriers - 3 are asymptomatic carriers and 3 are symptomatic carriers. 
A comparison between the BDI scales and total BDI median values in relation to the independent 
variables of this study was carried out: pensioners and unemployed present significantly higher values than the 
students and employed people regarding somatic or performance (p = 0.018) and total BDI (p = 0.027). 
Regarding the PST result, carriers present higher values than non-carriers with regard to cognitive-affective 
depression (p = 0.001), somatic or performance (p = 0.028) and total BDI (p = 0.002). Regarding current status, 
carriers present significantly higher values than non-carriers in relation to cognitive-affective depression (p = 
0.003), somatic or performance (p = 0.014) and total BDI (p = 0.004). Compared to carriers, symptomatic 
carriers have higher values than asymptomatic carriers. Regarding the time after PST result, subjects who 
underwent the PST a smaller number of years ago (≤ 5) present higher levels of cognitive affective depression (p 
= 0.041) and total depression (p = 0.040) than those who underwent the PST for more years (≥ 6). 
In Table 4, normative means of SAS scale and total SAS24,25 are presented to the general Portuguese 
population and to the Portuguese population with anxiety, as well as for the population in this study, i.e., subjects 
who took the PST for HD at least 3 years ago. 
When comparing the normative values of the general population of the SAS Portuguese version24 with 
the values of the present study, it can be stated that the present sample has lower values than those of the general 
population in all of the SAS scales and in total SAS, except in Central Nervous System Anxiety subscale, as it 
can be observed in Table 4. α values of the present sample are good - total SAS; questionable - motor anxiety; 
poor - cognitive anxiety and vegetative anxiety; and unacceptable - Central Nervous System Anxiety25. 
Table 4 
Comparison of SAS scales and Total SAS means for the general Portuguese population, Portuguese population 
with emotional disturbances and the population of the present study 
 
 
General Portuguese 
population  
Portuguese 
population with 
anxiety  
Population of the present 
study 
Ponciano et al.24  
SAS scales and total SAS M SD M SD M SD α 
Cognitive Anxiety 8.759 2.303 - - 7.560 2.002 0.55 
Motor Anxiety 6.824 2.047 - - 6.680 2.231 0.61 
Vegetative Anxiety 14.587 2.705 - - 13.840 3.287 0.55 
Central Nervous System Anxiety 3.237 1.278 - - 3.400 1.190 0.14 
Total SAS 33.406 6.611 46.03 9.591 31.480 7.422 0.83 
M = Mean; SD = Standard deviation; α = Cronbach's alpha 
The authors of SAS24 consider that the cutoff point is set to the value of 40. However, the value of 37 
already suggests a serious likelihood that the subject is pathologically anxious. Of the 29 subjects of the sample, 
22 (75.9%) present a value equal to or less than 39 and 7 subjects a value equal to or higher than 40. From these 
7 subjects, 5 are carriers - 3 are symptomatic and 2 are asymptomatic. 
A comparison between the SAS scales and total SAS median values in relation to the independent 
variables of this study was carried out: carriers have higher values than non-carriers with regard to cognitive 
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anxiety (p = 0.000), vegetative anxiety (p = 0.000), motor anxiety (p = 0.009), and total SAS (p = 0.000). 
Regarding carriers, symptomatic carriers have higher values than asymptomatic carriers. 
Spearman's rank correlation coefficient between BSI, BDI and SAS was calculated. The studied 
dimensions present mostly positive and statistically significant correlations between them (r = 0.399-.952). The 
dimensions presenting the least significant correlations with the other dimensions are the phobic anxiety (BSI) (r 
= 0.041-0.464), then the central nervous system anxiety (SAS) (r = 0.247-0.652). The dimensions vegetative 
anxiety (SAS) and motor anxiety (SAS) also present less significant correlations. 
The authors of this study wanted to know the correlations between the sociodemographic and clinical 
variables and the studied instruments, having found statistically significant results on the socio-demographic 
variable profession and on the clinical variables time after PST result, PST result and current status (Table 5). 
Only statistically significant results are presented. 
Analysing Table 5, it is possible to verify that the socio-demographic variable profession has a negative and 
significant correlation with anxiety (BSI), GSI (BSI), PSDI (BSI) and all BDI dimensions. Regarding the clinical 
variables, time after PST result, PST result and current status show significant correlations: time after PST result 
correlates negatively and significantly with somatization (BSI), all BSI indices (GSI, PSTI and PSDI), total BDI 
and the variable cognitive-affective depression (BDI). The PST result and the current status correlated positively 
and significantly with the same variables: obsession-compulsive, depression, anxiety, GSI and PSDI indices 
from BSI, all the dimensions of BDI and SAS, with the exception of the central nervous system anxiety (SAS). 
The result of the predictive test also correlates positively and significantly with hostility (BSI). 
Table 5 
Spearman's rank correlation coefficient or Spearman's rho for sociodemographic and clinical variables and BSI, BDI and 
SAS scales, indices and totals 
 Profession Time after PST result PST result Current status 
1 - BSI Somatization 
 -.468*   
 .017   
2 - BSI Obsessive-compulsive 
  .464* .541** 
  .015 .004 
3 - BSI Interpersonal Sensitivity     
4 - BSI Depression 
  .458* .461* 
  .016 .015 
5 - BSI Anxiety 
-.390*  .425* .440* 
.049  .031 .024 
6 - BSI Hostility 
  .382*  
  .049  
7 - BSI Phobic Anxiety     
8 - BSI Paranoid Ideation     
9 - BSI Psychoticism     
10 - BSI GSI 
-.425* -.415* .410* .440* 
.030 .035 .037 .025 
11 - BSI PSTI 
 -.371*   
 .047   
12 - BSI PSDI 
-.523** -.402* .617** .670** 
.007 .046 .001 .000 
13 -  BDI Cognitive-affective depression 
-.442* -.412* .671** .683** 
.024 .036 .000 .000 
14 - BDI Somatic or performance depression 
-.422*  .438* .536* 
.032  .025 .005 
15 - Total BDI 
-.497** -.411* .612** .660** 
.010 .037 .001 .000 
16 - SAS Cognitive Anxiety 
  .790** .783** 
  .000 .000 
17 - SAS Vegetative Anxiety 
  .697** .727** 
  .000 .000 
18 - SAS Motor Anxiety 
  .506** .578** 
  .007 .002 
19 - SAS Central Nervous System Anxiety     
20 – Total SAS 
  .752* .783** 
  .000 .001 
GSI = General Severity Index; PSTI = Positive Symptoms Total,  
PSDI = Positive Symptom Distress Index 
**Significant correlation to level 0.01/ * Significant correlation to level 0.05  
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4. Discussion 
The sample in this study is mostly female, married or in unmarried unions, with a mean age of 44.52 years, 
housekeeper, carrier and having performed the PST for about 5.72 years on average. Previous studies on middle 
and long-term PST psychological impact20,28 have suggested that female population – both carrier and non-
carrier - had higher values of psychopathology and tend to score higher in somatization, phobic anxiety and 
hostility dimensions28. However, in the present study, no differences in relation to gender were found. 
The majority of the sample did not reveal clinically significant psychopathological values, which is 
nonetheless surprising, since asymptomatic carriers generally have the prodrome of HD that may appear up to 
several years before the onset of motor symptoms4. Furthermore, carriers usually present psychiatric disorder, as 
HD is associated with affective disorders, irritability, apathy and psychosis6. However, this sample is composed 
by carriers and non-carriers and not just carriers. 
Although as a whole the sample does not show high values of psychopathology, depression and anxiety, 
there is disturbing data present. In particular, 6 subjects (20.7%) present a value equal to or greater than 1.7 of 
PSDI (BSI); 7 subjects (24.1%) have depression (BDI); and 7 subjects (24.1%) present a value equal to or 
greater than 40 of anxiety (SAS); and the overwhelming majority of these individuals is a carrier. That is, 
carriers, and primarily symptomatic carriers, clearly show higher values than non-carriers and even than 
asymptomatic carriers in the studied dimensions. These data corroborate the ones obtained by a study29, which 
suggests that subjects experiencing real symptoms are focalized on their physical sensations, leading them to feel 
worse than those subjects who have not yet experienced symptoms. 
Symptomatic patients present a higher PSDI, as well as higher values of obsession-compulsive than 
those of asymptomatic carriers and non-carriers. Moreover, carriers present higher values than non-carriers with 
regard to cognitive anxiety, vegetative anxiety, motor anxiety and total anxiety, and symptomatic carriers have 
higher values than asymptomatic carriers, for the same dimensions. The same can be said regarding the 
cognitive-affective depression, somatic or performance and total depression (BDI). These data are corroborated 
by the correlations between the current status and the studied dimensions.  
The subjects who underwent the PST for a smaller period of time present higher levels of cognitive-
affective depression and total depression than those who underwent the PST a higher period of time ago. The 
subjects who underwent the PST less time ago present a higher PSDI, as well as higher levels of somatization, 
anxiety and GSI. In several studies28, higher values of depression, anxiety and psychopathological symptoms 
were found in subjects who underwent the PST for fewer years, which confirms the results resulting from the 
present study. 
Pensioners and the unemployed present a higher PSDI and higher levels of somatic or performance 
depression and total depression. Pensioners and students present more phobic anxiety. These data are also 
corroborated by the correlations between the profession and the studied dimensions. 
It can be stated that carriers, especially symptomatic carriers, who underwent the PST less time ago, pensioners 
and unemployed are the ones that, in this sample, present worse psychopathological symptoms, depression and 
anxiety. It is difficult to distinguish in these carriers the psychopathological symptoms arising from the fact of 
knowing that they are carriers of this devastating disease and the psychopathological symptoms of the 
manifestation of the disease itself. In fact, although the specific psychopathology of these subjects is well 
documented5,6, the psychopathology comorbidity is also present7,8: suicidal ideation in HD frequently occurs and 
its assessment is a priority in mutation carriers with a depressed mood30. Furthermore, knowledge about the high 
suicide risk in this disease is important for genetic counselling10. 
 
5. Conclusion 
In the middle and long-term after receiving the PST result, subjects with this profile should have a more intense 
and personalized psychological and social support, aiming to prevent the risk of suicide and to improve the 
quality of their lives. 
 Future research should focus on the relationship between the quality of PST protocols and its 
psychological impact. 
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